Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 9 Melanoma 4 Neoplasms 3 Multiple Myeloma 3 Skin Neoplasms 2 Polycystic Ovary Syndrome 2 Venous Thromboembolism 1 Triple Negative Breast Neoplasms 1 Thrombocythemia, Essential 1 Stem Cell Transplant Complications 1 Skin Toxicity 1 Resectable Pancreatic Ductal Adenocarcinoma 1 Renal Insufficiency 1 Recurrence 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Polycythemia Vera 1 Obesity 1 Neoplasm Metastasis 1 Myeloproliferative Disorders 1 Meningioma 1 Lymphoma, Mantle-Cell 1 Lung Neoplasms 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia, B-Cell 1 Leukemia 1 Inflammation 1

Interventions

Hydroxyurea 7 Bevacizumab 7 Everolimus 6 lutetium Lu 177 dotatate 4 Magnetic Resonance Spectroscopy 4 pembrolizumab 3 abemaciclib 3 Sunitinib 3 Imatinib Mesylate 3 vistusertib 2 gallium Ga 68 dotatate 2 arginyllysine 2 aldesleukin 2 Whole Body Imaging 2 Specimen Handling 2 Radiotherapy 2 Octreotide 2 Nivolumab 2 Cyclophosphamide 2 Amino Acids 2 90Y-octreotide, DOTA-Tyr(3)- 2 vatalanib 1 tozuleristide 1 sargramostim 1 regorafenib 1 pasireotide 1 neratinib 1 fludarabine phosphate 1 fludarabine 1 dexamethasone acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Meningioma × Tablets × Clear all

NCT06275919 2026-05-13

MIRAGE

Istituto Oncologico Veneto IRCCS

Phase 2 Recruiting

Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡